New York University
nyu.eduTotal trials
119
Active
40
Phase 3
3
Total enrollment
62,470
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Combination NRT | — | — | — | — | — | 1 | |
| Supplemental Postoperative Bupivacaine | — | — | — | — | — | 1 |
Next readouts
- 2026-06-30
- 2028-06-30
Top conditions
- Depression7
- Speech Sound Disorder6
- HIV5
- HIV Infections4
- HIV/AIDS4
- Dental Fear3
- Childhood Apraxia of Speech3
- Psychosis3
Frequently asked questions about New York University
- How many clinical trials does New York University have on ClinicalTrials.gov?
- New York University is listed as the lead sponsor on 119 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
- How many of New York University's trials are in Phase 3?
- 3 of New York University's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does New York University focus on?
- New York University's most-studied conditions on ClinicalTrials.gov are Depression, Speech Sound Disorder, HIV, HIV Infections, HIV/AIDS.
- When are New York University's next clinical trial readouts?
- New York University has 2 upcoming primary-completion readouts tracked here; the soonest is “Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment”, expected around 2026-06-30.